Comerica Bank Has $830,000 Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Comerica Bank reduced its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 45.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,631 shares of the company's stock after selling 17,442 shares during the period. Comerica Bank's holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of KYMR. Wellington Management Group LLP lifted its stake in Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after acquiring an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Kymera Therapeutics by 3.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock worth $276,395,000 after purchasing an additional 224,859 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $5,887,000. Finally, Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock worth $196,617,000 after purchasing an additional 133,546 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at $2,064,510. This trade represents a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock valued at $324,567 in the last 90 days. 16.01% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on KYMR shares. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Guggenheim reaffirmed a "buy" rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday, May 12th. UBS Group cut their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday. Bank of America cut their price target on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research note on Monday, May 12th. Finally, Stephens reaffirmed an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $55.27.

Kymera Therapeutics Price Performance

Shares of KYMR stock traded up $0.23 during trading on Friday, reaching $30.25. The company had a trading volume of 440,383 shares, compared to its average volume of 561,687. The company has a market capitalization of $1.97 billion, a PE ratio of -12.93 and a beta of 2.18. The firm's 50 day simple moving average is $29.36 and its two-hundred day simple moving average is $37.05. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company's revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.69) EPS. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.